Genetic Diagnostic Centre

gdc-egypt.com

Genetic Diagnostic Center is a leading Egyptian medical center dedicated to delivering innovative medical genetics services for patients and other healthcare providers. In GDC, we combine 50 years of experience with the latest cutting-edge technologies to offer a quality driven performance in Cytogenetics, Molecular Genetics, Hematopathology, Flow Cytometry and Immunohistochemistry.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech, Industrial Impact

ATRECA AND XENCOR LAUNCH NEW PROGRAM TO DEVELOP T CELL ENGAGING BISPECIFIC ANTIBODY

Atreca, Inc. | February 07, 2023

news image

On February 6, 2023, Atreca, Inc. (Atreca), a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics, and Xencor, Inc., a clinical-stage biopharmaceutical company that develops cytokines and engineered antibodies for the treatment of autoimmune diseases and cancer, announced, as part of their existing strategic collaboration, that they have mutually selected the first progr...

Read More

PHARMACYTE BIOTECH ANNOUNCES IND SUBMITTED TO U.S. FDA FOR CLINICAL TRIAL IN LOCALLY ADVANCED, INOPERABLE PANCREATIC CANCER

PharmaCyte Biotech | September 02, 2020

news image

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for a planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC). PharmaCyte’s Chief Executive Officer, Kenneth L...

Read More

Medical

TESELAGEN BIOTECHNOLOGY ANNOUNCED THE LAUNCH OF A NEW PROTEIN OPTIMIZATION TOOLKIT FOR AUTOMATED BIOTHERAPEUTIC DRUG DESIGN AND DEVELOPMENT

TeselaGen Biotechnology | May 21, 2021

news image

TeselaGen Biotechnology today announced the launch of a new protein optimization toolkit for biotherapeutic drug design and development, introducing significant enhancements to the company’s flagship TeselaGen® OS to form designing and developing pharmaceuticals and biotherapeutics faster and fewer expensive. The new capabilities, easily accessible via the cloud-based platform, simplify the planning of highly complex combinatorial protein libraries and support AI models for optimizing ...

Read More

Research

TURTLETREE LAUNCHES NEW RESEARCH AND DEVELOPMENT FACILITY IN GREATER SACRAMENTO

TurtleTree | October 04, 2021

news image

TurtleTree has officially opened its new R&D facility in California's state capital. Located in West Sacramento, this 24,000-square-foot building will house a world-class research hub showcasing the company's extensive array of innovations and cell-based technologies. Representing a milestone in TurtleTree's US-based expansion plans, the research facility will spur the development of precision fermentation technology currently used to produce valuable milk in...

Read More
news image

MedTech, Industrial Impact

ATRECA AND XENCOR LAUNCH NEW PROGRAM TO DEVELOP T CELL ENGAGING BISPECIFIC ANTIBODY

Atreca, Inc. | February 07, 2023

On February 6, 2023, Atreca, Inc. (Atreca), a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics, and Xencor, Inc., a clinical-stage biopharmaceutical company that develops cytokines and engineered antibodies for the treatment of autoimmune diseases and cancer, announced, as part of their existing strategic collaboration, that they have mutually selected the first progr...

Read More
news image

PHARMACYTE BIOTECH ANNOUNCES IND SUBMITTED TO U.S. FDA FOR CLINICAL TRIAL IN LOCALLY ADVANCED, INOPERABLE PANCREATIC CANCER

PharmaCyte Biotech | September 02, 2020

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for a planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC). PharmaCyte’s Chief Executive Officer, Kenneth L...

Read More
news image

Medical

TESELAGEN BIOTECHNOLOGY ANNOUNCED THE LAUNCH OF A NEW PROTEIN OPTIMIZATION TOOLKIT FOR AUTOMATED BIOTHERAPEUTIC DRUG DESIGN AND DEVELOPMENT

TeselaGen Biotechnology | May 21, 2021

TeselaGen Biotechnology today announced the launch of a new protein optimization toolkit for biotherapeutic drug design and development, introducing significant enhancements to the company’s flagship TeselaGen® OS to form designing and developing pharmaceuticals and biotherapeutics faster and fewer expensive. The new capabilities, easily accessible via the cloud-based platform, simplify the planning of highly complex combinatorial protein libraries and support AI models for optimizing ...

Read More
news image

Research

TURTLETREE LAUNCHES NEW RESEARCH AND DEVELOPMENT FACILITY IN GREATER SACRAMENTO

TurtleTree | October 04, 2021

TurtleTree has officially opened its new R&D facility in California's state capital. Located in West Sacramento, this 24,000-square-foot building will house a world-class research hub showcasing the company's extensive array of innovations and cell-based technologies. Representing a milestone in TurtleTree's US-based expansion plans, the research facility will spur the development of precision fermentation technology currently used to produce valuable milk in...

Read More